Nospharma Wins McGill University DemoDay

We are proud to announce an exciting win victory for Nospharma, as our CEO, Anmol Nagpal, won the Jury Award at McGill University/NeruoSphere’s Demo Day. This recognition not only highlights the innovative strides we are making in the rare neurological disease space industry but also solidifies our place as a leader in the development of therapeutics for Fragile X syndrome, SynGAP1 Disorder, GRIN Disorder, and Phelan-McDermid Syndrome.

Our Winning Pitch: NOS-01 to treat Fragile X Syndrome

Nospharma presented our most advanced asset and indication project, NOS-01 to transform the treatment landscape for Fragile X Syndrome.

The pitch detailed our innovative approach, underlying technology, and the potential impact on both patient outcomes and the broader healthcare ecosystem. The response from the competition judges and attendees was overwhelmingly positive, underscoring the urgency and need for such advancements in the field.

Nopharma was awarded the top Jury Award and cash prize by a panel of 6 venture capital firms and industry leaders, with fierce competition from multiple other McGill spin-off companies.